⌕
Zenas Biopharma · ZBIO · Nasdaq
Tenet 29 · Weak
Compare
$27.75−0.64%At closeTenet 29 · Weak
$27.75−0.18 (−0.64%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Zenas Biopharma (ZBIO) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

13 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 80% below its peak, net margin −3777.4%.
The four lines that matter · FY23–FY25
Revenue ($M)▲100.0%
10.0
FY23→FY25CAGR −55.3%/yr
Net income ($M)▼140.6%
−377.7
FY23→FY25CAGR —
Free cash flow ($M)▼43.9%
−172.4
FY23→FY25CAGR —
Diluted EPS▲29.0%
−8.44
FY23→FY25CAGR —
What the income statement says · FY23–FY25
Where every revenue dollar goes · FY25 ($M)10.0Revenue0.0COGS−339.7R&D−53.3SG&A−383.1Op income5.3Tax & other−377.7Net income

-3777¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Operating Net
108530%sector median net margin ~3%FY23FY25

Net margin -3777.4% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.

The receipt · income statement · FY23–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.6762, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23YoYCAGR 23→25
Revenue & profitability
Revenue
11,000.010,000.05,000.050,000.0▲100.0%−55.3%
Cost of revenue
—0.00.00.0——
Gross profit
—A—A—A—A——
Research & development
461,717.0339,735.0139,139.070,033.0▲144.2%+120.3%
Selling, general & admin
75,685.053,322.029,749.017,114.0▲79.2%+76.5%
Total operating expenses
537,402.0393,057.0168,888.087,147.0▲132.7%+112.4%
Operating incomefeeds ROC rank
−526,402.0−383,057.0−163,888.0−37,147.0▼133.7%—
Other income, net
−15,137.05,241.07,329.0324.0——
Pretax income
−541,539.0−377,816.0−156,559.0−36,823.0▼141.3%—
Income tax
269.0−79.0429.0301.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−541,808.0−377,737.0−156,988.0−37,124.0▼140.6%—
Per share
Diluted EPSbuyback-sensitive
−10.05−8.44−11.89−24.25▲29.0%—
Diluted shares (mn)
66.1544.7313.201.53▲238.9%+440.5%
Margins
Gross margin
—A—A—A—A——
Operating margin
−4785.5%−3830.6%−3277.8%−74.3%▼552.8pp−3756.3pp
Net margin
−4925.5%−3777.4%−3139.8%−74.2%▼637.6pp−3703.1pp
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
CSV export is on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-16 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Zenas Biopharma's revenue last fiscal year?

Zenas Biopharma reported revenue of $10.0M in fiscal 2025, up 100.0% from fiscal 2024.

What was Zenas Biopharma's net income?

Zenas Biopharma reported net income of −$377.7M in fiscal 2025, a net margin of −3777.4%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.